NEW YORK and SAN DIEGO, April 26, 2012 (GLOBE NEWSWIRE) -- Valence Life Sciences, the independent entity formed in 2012 as successor to Caxton Advantage Venture Partners, announces the promotion of Scott Morenstein to Managing Director. Mr. Morenstein joined Caxton Advantage in 2007 as an Associate after receiving an MBA from Harvard Business School. Mr. Morenstein started his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein played a key role in the sale of Caxton Advantage portfolio company Gemin X Pharmaceuticals to Cephalon (now Teva Pharmaceutical) and his deals include investments in Sunesis and ArQule. Valence Life Sciences further announces the hiring of Robert Ferraioli, CPA as Vice President, Controller. Mr. Ferraioli will be responsible for overseeing Valence Life Sciences’ accounting and administrative functions. Mr. Ferraioli has a diverse and extensive accounting background with experience in asset management, public accounting, and financial services. Mr. Ferraioli joins Valence Life Sciences from Automotive Resources International where he was responsible for the development of financial forecasts and strategic planning models. He was formerly Assistant Controller at Caxton Associates where he worked from 2000 to 2009.
